Targeting Extracellular NAMPT and TLR4 as a Therapy for Pulmonary Arterial Hypertension

Technology #ua17-159

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Categories
Researchers
Joe G.N. Garcia
Professor, Medicine
Managed By
Rakhi Gibbons
Asst. Director, Life Sciences (520) 626-6695

Title: Targeting Extracellular NAMPT and TLR4 as a Therapy for Pulmonary Arterial Hypertension

 

Invention: The invention is the targeting of nicotinamide phosphoribosyltransferase (NAMPT) for the treatment of pulmonary arterial hypertension.

 

Background: Pulmonary arterial hypertension is a progressive disease that leads to increased resistance and eventual right ventricular failure and death. Unfortunately, current therapies are severely limited. NAMPT is a novel therapeutic target because NAMPT increases resistance to cell death, cell proliferation, and smooth muscle cell survival. NAMPT may play an important role in the prevention of pulmonary vascular remolding.

 

Applications:

  • Pharmaceuticals
  • Diagnostics
  • Clinical research tools

 

Advantages:

  • Addresses an unmet need in the treatment of pulmonary arterial hypertension
  • Research into pathology of pulmonary arterial hypertension can lead to novel therapies such as small molecule drugs

 

Licensing Manager:

Rakhi Gibbons

RakhiG@tla.arizona.edu

(520) 626-6695